1. Home
  2. PRG vs KLRA Comparison

PRG vs KLRA Comparison

Compare PRG & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$32.47

Market Cap

1.6B

ML Signal

HOLD

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$11.29

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRG
KLRA
Founded
2020
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
PRG
KLRA
Price
$32.47
$11.29
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $50.00
N/A
AVG Volume (30 Days)
536.4K
★ 927.7K
Earning Date
04-29-2026
N/A
Dividend Yield
★ 1.45%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.80
N/A
Revenue
★ $2,409,223,000.00
N/A
Revenue This Year
$23.77
N/A
Revenue Next Year
$7.91
N/A
P/E Ratio
$18.08
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$25.80
$11.77
52 Week High
$47.73
$23.82

Technical Indicators

Market Signals
Indicator
PRG
KLRA
Relative Strength Index (RSI) 22.77 29.27
Support Level $32.30 N/A
Resistance Level $33.81 $19.15
Average True Range (ATR) 1.18 0.97
MACD -0.34 -0.14
Stochastic Oscillator 5.35 3.87

Price Performance

Historical Comparison
PRG
KLRA

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Share on Social Networks: